Shenzhen Third People’s Hospital Reports Findings in Hepatitis C Virus (Prevalence, diagnosis, and treatment of hepatitis C in Mainland China): Liver Diseases and Conditions – Hepatitis C Virus

2021 DEC 01 (NewsRx) -- By a News Reporter-Staff News Editor at Daily China News -- New research on Liver Diseases and Conditions - Hepatitis C Virus is the subject of a report. According to news reporting originating from Shenzhen, People’s Republic of China, by NewsRx correspondents, research stated, “Infection with the hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma in China. Rapid economic development has had an enormous impact on the epidemiology and treatment of hepatitis C.”

Our news editors obtained a quote from the research from Shenzhen Third People’s Hospital, “The prevalence of anti-HCV antibodies in Mainland China is approximately 0.91%, and use of injected drugs has become the main route of HCV transmission in China. Reimbursement for 3 direct-acting antivirals (DAAs) has been approved by the National Medical Insurance scheme in China, which ensures the accessibility of treatment for an HCV infection. To improve the awareness of treatments for hepatitis C among medical personnel and the rate of in-hospital screening for HCV, the Chinese Medical Association has formulated guidelines for the diagnosis and treatment of hepatitis C and a process of in-hospital screening for hepatitis C in China. These efforts have standardized the screening, diagnosis, treatment, and management of hepatitis C. Based on the international strategy for micro-elimination of hepatitis C, China has also screened and treated groups at risk of hepatitis C infection, and this has reduced the number of the infected.”

According to the news editors, the research concluded: “The current review describes the status of and issues with the prevalence, diagnosis, and treatment of hepatitis C in Mainland China as part of the global effort to eliminate viral hepatitis by 2030.”

This research has been peer-reviewed.

For more information on this research see: Prevalence, diagnosis, and treatment of hepatitis C in Mainland China. Global Health & Medicine, 2021;3(5):270-275.

The news editors report that additional information may be obtained by contacting Hongzhou Lu, Dept. of Infections Disease, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of China.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.35772/ghm.2021.01080. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)